We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current LCTX market cap is 114.25M. The company's latest EPS is USD -0.1138 and P/E is -5.18.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.25M | 2.09M | 1.44M | 1.41M | 3.78M |
| Operating Income | -6.71M | -6.36M | -6.66M | -5.87M | -3.84M |
| Net Income | -7.11M | -4.78M | -6.54M | -5.76M | -3.03M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 3.52M | 1.83M | 4.34M | 14.7M | 8.95M |
| Operating Income | -38.88M | -26.45M | -49.21M | -22.52M | -24.73M |
| Net Income | -11.71M | -20.65M | -43.02M | -26.27M | -21.49M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 106.15M | 101.02M | 108.48M | 102.8M | 96.59M |
| Total Liabilities | 39.49M | 39M | 37.49M | 35.93M | 31.8M |
| Total Equity | 66.66M | 62.02M | 70.99M | 66.88M | 64.79M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 125.48M | 107.95M | 174.55M | 123.66M | 101.02M |
| Total Liabilities | 14.23M | 12.82M | 83.65M | 51.73M | 39M |
| Total Equity | 111.25M | 95.13M | 90.9M | 71.94M | 62.02M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -22.55M | -28.57M | -5.78M | -10.96M | -16.75M |
| Investing | 36.71M | 46.45M | -38k | -8.83M | -4.94M |
| Financing | 6.44M | 6.42M | 14.02M | 14.13M | 14.12M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -31.95M | -19.75M | -23.56M | 1.06M | -28.57M |
| Investing | 16.96M | 13.04M | 9.75M | -46.16M | 46.45M |
| Financing | 617k | 29.87M | 36.93M | 1.63M | 6.42M |
| Market Cap | 114.25M |
| Price to Earnings Ratio | -5.18 |
| Price to Sales Ratio | 12.45 |
| Price to Cash Ratio | 3.14 |
| Price to Book Ratio | 1.8 |
| Dividend Yield | - |
| Shares Outstanding | 188.84M |
| Average Volume (1 week) | 798.72k |
| Average Volume (1 Month) | 2.46M |
| 52 Week Change | -42.38% |
| 52 Week High | 1.61 |
| 52 Week Low | 0.481 |
| Spread (Intraday) | 0.01 (0.83%) |
| Company Name | Lineage Cell Therapeutics Inc |
| Address |
2173 salk avenue alameda, california 92008 |
| Website | https://lineagecell.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
